Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Dermatophytic Onychomycosis Therapeutics (DOT) Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Topical
      • 1.3.3 Oral Therapy
    • 1.4 Market Segment by Application
      • 1.4.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Dermatology And Podiatry Clinics
      • 1.4.4 Independent Pharmacies
      • 1.4.5 Mail Order Pharmacies
      • 1.4.6 Drug Stores
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size
      • 2.1.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue 2014-2025
      • 2.1.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales 2014-2025
    • 2.2 Dermatophytic Onychomycosis Therapeutics (DOT) Growth Rate by Regions
      • 2.2.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales by Regions 2014-2019
      • 2.2.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Dermatophytic Onychomycosis Therapeutics (DOT) Sales by Manufacturers
      • 3.1.1 Dermatophytic Onychomycosis Therapeutics (DOT) Sales by Manufacturers 2014-2019
      • 3.1.2 Dermatophytic Onychomycosis Therapeutics (DOT) Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Dermatophytic Onychomycosis Therapeutics (DOT) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Dermatophytic Onychomycosis Therapeutics (DOT) Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Concentration Ratio (CR5 and HHI)
    • 3.3 Dermatophytic Onychomycosis Therapeutics (DOT) Price by Manufacturers
    • 3.4 Key Manufacturers Dermatophytic Onychomycosis Therapeutics (DOT) Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Dermatophytic Onychomycosis Therapeutics (DOT) Market
    • 3.6 Key Manufacturers Dermatophytic Onychomycosis Therapeutics (DOT) Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Topical Sales and Revenue (2014-2019)
      • 4.1.2 Oral Therapy Sales and Revenue (2014-2019)
    • 4.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales Market Share by Type
    • 4.3 Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue Market Share by Type
    • 4.4 Dermatophytic Onychomycosis Therapeutics (DOT) Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales by Application

    6 United States

    • 6.1 United States Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Company
    • 6.2 United States Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Type
    • 6.3 United States Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Application

    7 European Union

    • 7.1 European Union Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Company
    • 7.2 European Union Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Type
    • 7.3 European Union Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Application

    8 China

    • 8.1 China Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Company
    • 8.2 China Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Type
    • 8.3 China Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Company
    • 9.2 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Type
    • 9.3 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Application
    • 9.4 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Breakdown Data by Countries
      • 9.4.1 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Sales by Countries
      • 9.4.2 Rest of World Dermatophytic Onychomycosis Therapeutics (DOT) Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Galderma
      • 10.1.1 Galderma Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Dermatophytic Onychomycosis Therapeutics (DOT)
      • 10.1.4 Dermatophytic Onychomycosis Therapeutics (DOT) Product Introduction
      • 10.1.5 Galderma Recent Development
    • 10.2 Bausch Health
      • 10.2.1 Bausch Health Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Dermatophytic Onychomycosis Therapeutics (DOT)
      • 10.2.4 Dermatophytic Onychomycosis Therapeutics (DOT) Product Introduction
      • 10.2.5 Bausch Health Recent Development
    • 10.3 Novartis
      • 10.3.1 Novartis Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Dermatophytic Onychomycosis Therapeutics (DOT)
      • 10.3.4 Dermatophytic Onychomycosis Therapeutics (DOT) Product Introduction
      • 10.3.5 Novartis Recent Development
    • 10.4 Pfizer
      • 10.4.1 Pfizer Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Dermatophytic Onychomycosis Therapeutics (DOT)
      • 10.4.4 Dermatophytic Onychomycosis Therapeutics (DOT) Product Introduction
      • 10.4.5 Pfizer Recent Development
    • 10.5 Janssen
      • 10.5.1 Janssen Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Dermatophytic Onychomycosis Therapeutics (DOT)
      • 10.5.4 Dermatophytic Onychomycosis Therapeutics (DOT) Product Introduction
      • 10.5.5 Janssen Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Dermatophytic Onychomycosis Therapeutics (DOT) Sales Channels
      • 11.2.2 Dermatophytic Onychomycosis Therapeutics (DOT) Distributors
    • 11.3 Dermatophytic Onychomycosis Therapeutics (DOT) Customers

    12 Market Forecast

    • 12.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales and Revenue Forecast 2019-2025
    • 12.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales Forecast by Type
    • 12.3 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales Forecast by Application
    • 12.4 Dermatophytic Onychomycosis Therapeutics (DOT) Forecast by Regions
      • 12.4.1 Global Dermatophytic Onychomycosis Therapeutics (DOT) Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Dermatophytic Onychomycosis Therapeutics (DOT) Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin America are expected to impede growth of the global dermatophytic onychomycosis therapeutics market.
      The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.
      In 2019, the market size of Dermatophytic Onychomycosis Therapeutics (DOT) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Dermatophytic Onychomycosis Therapeutics (DOT).

      This report studies the global market size of Dermatophytic Onychomycosis Therapeutics (DOT), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Dermatophytic Onychomycosis Therapeutics (DOT) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Galderma
      Bausch Health
      Novartis
      Pfizer
      Janssen
      ...

      Market Segment by Product Type
      Topical
      Oral Therapy

      Market Segment by Application
      Hospitals
      Dermatology And Podiatry Clinics
      Independent Pharmacies
      Mail Order Pharmacies
      Drug Stores

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Dermatophytic Onychomycosis Therapeutics (DOT) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Dermatophytic Onychomycosis Therapeutics (DOT) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Dermatophytic Onychomycosis Therapeutics (DOT) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now